Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?
Many trials in myeloma are stratified on cytogenetic abnormalities. Among them, the most commonly chosen are the t(4;14), the del(17p), and the t(14;16). If data are well established for t(4;14) and del(17p), very few data support the use of t(14;16). To address this issue, we retrospectively analyzed 1003 patients with newly diagnosed myeloma for this abnormality. We identified 32 patients with the t(14;16). Compared with patients lacking the t(14;16), we did not observe any difference in overall survival (P = .28). Moreover, in multivariate analyses, the t(14;16) was not prognostic (P = .39). In conclusion, our data do not support the use of t(14;16)-specific probes in the diagnostic panels of multiple myeloma.
Hematology Laboratory, University Hospital, and Inserm U892, Nantes, France. havetloiseau@chu-nantes.fr
Hervé
H
Avet-Loiseau
Florent
F
Malard
Loic
L
Campion
Florence
F
Magrangeas
Catherine
C
Sebban
Bruno
B
Lioure
Olivier
O
Decaux
Thierry
T
Lamy
Laurence
L
Legros
Jean-Gabriel
JG
Fuzibet
Mauricette
M
Michallet
Bernadette
B
Corront
Pascal
P
Lenain
Cyrille
C
Hulin
Claire
C
Mathiot
Michel
M
Attal
Thierry
T
Facon
Jean-Luc
JL
Harousseau
Stephane
S
Minvielle
Philippe
P
Moreau
D000368:Aged; D002883:Chromosomes, Human, Pair 14 / Q000235:genetics*; D002885:Chromosomes, Human, Pair 16 / Q000235:genetics*; D006801:Humans; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000235:genetics*; D015999:Multivariate Analysis; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D014178:Translocation, Genetic